Novartis gets final EC nod for Votubia

Novartis ($NVS) has won European approval for Votubia as a treatment for a rare type of brain tumor known as subependymal giant cell astrocytoma associated with tuberous sclerosis complex. With the same active ingredient as the kidney cancer drug Afinitor, Votubia is the first drug approved for these tumors. Release | Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.